MiniMed Completes Separation from Medtronic; Medtronic Exits Entire Stake
MMED sits 68% above its 52-week low of $10.65 on elevated volume (4.9× avg).
Summary
MiniMed completed its separation from Medtronic on October 15, 2026, with Medtronic exchanging 55.0M ordinary shares for 252.8M MiniMed shares and exiting its entire stake. The offer was 5.4x subscribed, and four Medtronic-affiliated directors resigned as the board was reduced from 11 to eight.
Key Events · M&A and Partnerships · MMED
-
Medtronic Exchange Offer Completed
Medtronic accepted 55,032,401 ordinary shares in exchange for 252,813,348 newly issued MiniMed shares on October 15, 2026, completing the separation.
-
Medtronic Exits Entire MiniMed Stake
Medtronic no longer owns any MiniMed common stock; MiniMed is now a fully independent company. The exchange offer was 5.4x subscribed.
-
Four Directors Resign, Board Shrinks to Eight
Linnea Burman, Scott Cundy, Laura Mauri, and Matthew R. Walter resigned effective October 15, 2026. The board decreased from 11 to eight members.
-
Amy Bricker Appointed Independent Director
Amy Bricker, EVP and Chief Enterprise Pharmacy Officer of Walgreen Co., was appointed as a Class II director and member of the Nominating and Corporate Governance Committee.
Analysis · MMED · Industrial Applications And Services
Medtronic's exchange offer closed on October 15, 2026, with Medtronic accepting 55,032,401 of its own ordinary shares in exchange for 252,813,348 newly issued MiniMed shares. Medtronic now owns zero MiniMed stock, completing the full separation and making MiniMed a standalone public company. The offer was 5.4x subscribed, indicating strong demand for MiniMed shares. In connection with the separation, four Medtronic-affiliated directors resigned and the board shrank from 11 to eight members, with Amy Bricker (EVP and Chief Enterprise Pharmacy Officer of Walgreen Co.) appointed as an independent Class II director. The governance changes signal a clean break from Medtronic's control and a reconstituted board focused on independent oversight.
How filings like this one have moved
In the 30 days to Oct 30, 2026, 38.3% of the 896 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.41%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MMED was trading at $17.90 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $5.1B. The 52-week trading range was $10.65 to $24.43. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.